Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Next Previous
X
Search
Trial Profile

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Neratinib (Primary)
  • Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 23 Sep 2022 Status changed from not yet recruiting to recruiting.
    • 31 Aug 2022 Planned End Date changed from 1 Nov 2023 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top